James Richard Porter Sells 9,543 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 9,543 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $97.16, for a total value of $927,197.88. Following the sale, the chief executive officer directly owned 278,629 shares in the company, valued at $27,071,593.64. This represents a 3.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

James Richard Porter also recently made the following trade(s):

• On Monday, January 5th, James Richard Porter sold 17,890 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $1,741,054.80.
• On Thursday, October 16th, James Richard Porter sold 27,000 shares of Nuvalent stock. The shares were sold at an average price of $90.63, for a total value of $2,447,010.00.

Nuvalent Stock Performance

Shares of NUVL traded up $9.62 during midday trading on Wednesday, hitting $106.82. The company had a trading volume of 895,694 shares, compared to its average volume of 779,373. Nuvalent, Inc. has a 1 year low of $55.53 and a 1 year high of $112.88. The firm has a market capitalization of $7.77 billion, a P/E ratio of -20.08 and a beta of 1.32. The company’s 50-day simple moving average is $102.57 and its 200-day simple moving average is $88.78.

Nuvalent (NASDAQ:NUVL) last issued its earnings results on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period in the previous year, the business posted ($1.28) EPS. Equities analysts predict that Nuvalent, Inc. will post -3.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on NUVL. Cantor Fitzgerald began coverage on shares of Nuvalent in a research note on Wednesday, October 15th. They issued an “overweight” rating and a $135.00 price objective on the stock. Leerink Partners increased their target price on Nuvalent from $140.00 to $149.00 and gave the company an “outperform” rating in a report on Monday, November 17th. HC Wainwright lifted their price target on shares of Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, November 17th. The Goldman Sachs Group raised their price objective on Nuvalent from $120.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, Piper Sandler raised their target price on shares of Nuvalent from $112.00 to $128.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. Fifteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $138.33.

Trending Headlines about Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

Institutional Investors Weigh In On Nuvalent

Several hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in shares of Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after purchasing an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Nuvalent in the third quarter valued at about $38,000. Eastern Bank acquired a new stake in Nuvalent during the third quarter valued at approximately $52,000. Persistent Asset Partners Ltd acquired a new stake in Nuvalent during the second quarter valued at approximately $88,000. Finally, Farther Finance Advisors LLC lifted its holdings in Nuvalent by 9,230.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock worth $93,000 after buying an additional 1,200 shares during the last quarter. Institutional investors own 97.26% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.